Paper Details

  1. Home
  2. Paper Details

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.

Author: HaradaNaoki, HayashiNorio, HiramatsuNaoki, ImaiYasuharu, InuiYoshiaki, KanekoAkira, KasaharaAkinori, MiyagiTakuya, MorishitaNaoki, OshitaMasahide, OzeTsugiko, SuzukiKunio, TakeharaTetsuo, TamuraShinji, TatsumiTomohide, YakushijinTakayuki, YamadaAkira, YamadaRyoko, YoshidaYuichi, YoshiharaHarumasa

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Triple therapy with telaprevir (TVR), pegylated interferon, and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, TVR causes severe adverse effects. This study examines the antiviral efficacy and safety of reduced administration of TVR in patients with CH-C.
Paper Details　
Original Abstract of the Article :
Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antivi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00535-014-0965-8

データ提供：米国国立医学図書館（NLM）

Finding a Balance: Telaprevir Dosing for HCV Genotype 1

In the vast desert of chronic hepatitis C (CH-C) treatment, finding the right balance between efficacy and safety is crucial. This prospective, randomized study investigates the efficacy and safety of telaprevir (TVR) at reduced doses (1500 or 2250 mg) in combination with pegylated interferon and ribavirin in Japanese patients with HCV genotype 1. Like a caravan leader adjusting the route based on the terrain, researchers explored the optimal dosage of TVR to maximize its benefits while minimizing potential side effects.

A New Oasis: Exploring Reduced Dosing Strategies

This study highlights the importance of finding the right balance between efficacy and safety in antiviral therapy. By investigating the effectiveness of reduced TVR doses, researchers are exploring a potential new oasis in the desert of CH-C treatment. It is like discovering a shortcut through the desert, offering a faster and safer journey for patients. The study findings provide valuable insights into the optimal dosage of TVR and its potential for improving treatment outcomes while mitigating adverse effects.

A Journey of Precision: Optimizing Treatment Strategies

This study underscores the need for precision in antiviral therapy. By carefully considering the individual needs of patients and exploring different dosing strategies, we can optimize treatment outcomes and ensure a better journey for those battling CH-C. This study offers a valuable roadmap for future research in this area, guiding us towards more effective and patient-centered treatment approaches.

Dr. Camel's Conclusion

This study provides valuable insights into the efficacy and safety of telaprevir at reduced doses for HCV genotype 1. The findings suggest that reducing the dosage of TVR may offer a balance between effectiveness and safety, potentially paving the way for a new oasis in the desert of CH-C treatment. It is a reminder that finding the optimal balance between efficacy and safety is crucial for improving patient outcomes in this challenging disease.

Date :
  1. Date Completed 2015-11-17
  2. Date Revised 2022-08-01
Further Info :

Pubmed ID

24806033

DOI: Digital Object Identifier

10.1007/s00535-014-0965-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.